Q-omics provides the consensus-scored FMO7P profile across patient tissues and cancer cell-line models. FMO7P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, FMO7P is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FMO7P RNA expression shows 12,574 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, KIRC, and THYM as cancer lineages where FMO7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FMO7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FMO7P survival associations across molecular data types. FMO7P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FMO7P RNA expression–survival associations across cancer types. High FMO7P expression shows unfavorable associations in KIRC and KIRP, but favorable associations in READ, SKCM, OV and ESCA. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for FMO7P RNA expression.
This table summarizes FMO7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FMO7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FMO7P shows higher tumor expression in KIRC, KIRP, COAD, BRCA, STAD and HNSC. The KIRC box plot shows higher FMO7P RNA expression in tumor versus normal tissue (log2 FC = +0.097, t-test p < 0.001).
This table shows molecular features associated with FMO7P in patient tissues and cancer cell lines. In patient samples, FMO7P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
